ALDX — Aldeyra Therapeutics, Inc. Stock Price, Chart & AI Report

Negative May 29, 2026 • 01:55 UTC GlobeNewswire Inc. • Rosen Law Firm

היום המועד האחרון לתביעה ייצוגית נגד ALDX: רוזן, חברה שפתחה בהליכים ראשונה, מעודדת משקיעים ב-Aldeyra Therapeutics, Inc עם הפסדים של יותר מ-100 אלף דולר לקבל ייעוץ משפטי לפני המועד החשוב ב-29 במאי בתביעה ייצוגית לניירות ערך שהוגשה לראשונה על ידי המשרד – ALDX

The Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding inconsistent clinical trial results for reproxalap and failed to disclose material information about the company's business and operations, resulting in investor losses.

ALDX class action lawsuit securities fraud clinical trial results investor losses reproxalap misleading statements

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements regarding clinical trial results for its drug candidate reproxalap. Investors allegedly suffered significant losses due to inconsistent trial data and undisclosed material information about the company's business operations.

Negative May 28, 2026 • 19:36 UTC GlobeNewswire Inc. • Rosen Law Firm

B&W DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BW

Rosen Law Firm is notifying investors in Babcock & Wilcox Enterprises, Aldeyra Therapeutics, and ChampionX Corporation of ongoing securities class action lawsuits. The B&W lawsuit alleges the company made false statements regarding a Power Generation contract with Applied Digital, with its largest shareholder BRC standing on both sides of the deal. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines.

BW BWNB BWPA ALDX securities class action false statements investor losses lead plaintiff deadline

Sentiment note

Company is subject to securities class action lawsuit with an imminent May 29 deadline, indicating serious investor allegations, though specific details are not provided in the article excerpt.

Negative May 26, 2026 • 21:45 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th

A class action lawsuit has been filed against Aldeyra Therapeutics (ALDX) for allegedly issuing false and misleading statements regarding reproxalap clinical trial results. The lawsuit claims the trial results were inconsistent and unreliable. Investors who purchased shares between November 3, 2023 and March 16, 2026 have until May 29, 2026 to apply as lead plaintiff.

ALDX class action lawsuit clinical trial results misleading statements reproxalap securities fraud lead plaintiff deadline

Sentiment note

The company faces a class action lawsuit alleging false and misleading statements about clinical trial results for reproxalap, with claims that trial results were inconsistent and unreliable. This represents significant legal and reputational risk to the company.

Negative May 25, 2026 • 00:34 UTC GlobeNewswire Inc. • Rosen Law Firm

מועד אחרון לתביעה ייצוגית נגד ALDX: רוזן, יועץ גלובלי מוביל, מעודד משקיעים ב-Aldeyra Therapeutics, Inc עם הפסדים של יותר מ-100 אלף דולר להשיג ייעוץ משפטי לפני המועד החשוב ב-29 במאי בתביעה ייצוגית לניירות ערך שהוגשה לראשונה על ידי המשרד – ALDX

Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) who purchased securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding reproxalap clinical trial results and failed to disclose inconsistencies that rendered positive findings unreliable, causing investor losses.

ALDX class action lawsuit securities fraud clinical trial results reproxalap investor losses May 29 deadline false statements

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding clinical trial results for its drug reproxalap. Allegations include false statements about trial consistency and undisclosed inconsistencies that undermined the reliability of positive findings, resulting in investor losses.

Negative May 25, 2026 • 00:34 UTC GlobeNewswire Inc. • Rosen Law Firm

ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm – ALDX

Rosen Law Firm reminds investors of Aldeyra Therapeutics who purchased securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements regarding reproxalap clinical trial results, claiming the results were inconsistent and unreliable, causing investor damages.

ALDX securities class action Aldeyra Therapeutics reproxalap clinical trial results lead plaintiff deadline investor losses misleading statements

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about clinical trial results for its drug candidate reproxalap. The lawsuit claims inconsistent trial results were misrepresented to investors, resulting in financial damages.

Negative May 20, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. alleging that the company made false and misleading statements regarding reproxalap clinical trial results. The complaint claims trial results were inconsistent and unreliable, rendering defendants' statements about the company's business and prospects materially false. Investors who purchased Aldeyra securities between November 3, 2023 and March 16, 2026 may be eligible to join the case.

ALDX class action lawsuit securities fraud clinical trial results reproxalap investor harm misleading statements

Sentiment note

The company is accused of making false and misleading statements about clinical trial results for its drug candidate reproxalap. Allegations of inconsistent trial results and lack of reliable positive findings indicate potential fraud and misrepresentation to investors, resulting in investor harm.

Negative May 20, 2026 • 12:00 UTC GlobeNewswire Inc. • Holzer & Holzer, Llc

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Vital Farms, Inc. (VITL), Super Micro Computer, Inc. (SMCI), and Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against three companies: Vital Farms (VITL) for alleged false statements regarding enterprise resource planning system implementation, Super Micro Computer (SMCI) for alleged non-disclosure of export control compliance issues, and Aldeyra Therapeutics (ALDX) for alleged misstatements regarding reproxalap clinical trials. All deadlines are set for late May 2026.

VITL SMCI ALDX shareholder class action lead plaintiff deadline securities litigation false statements material disclosure

Sentiment note

Company is defendant in shareholder class action lawsuit alleging false and misleading statements regarding reproxalap clinical trials, indicating potential clinical trial misrepresentation and shareholder losses.

Negative May 18, 2026 • 22:45 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

Rosen Law Firm is soliciting investors who purchased securities in Aldeyra Therapeutics, Babcock & Wilcox Enterprises, and Upstart Holdings during specified periods to join securities class action lawsuits. The firm alleges that defendants made false or misleading statements regarding clinical trial results, business operations, and financial prospects. Investors have until May 29, 2026 to serve as lead plaintiffs.

ALDX BW BWNB BWPA securities class action investor lawsuit false statements clinical trials

Sentiment note

Company is subject to securities class action lawsuit alleging false and misleading statements about reproxalap clinical trial results and business prospects, indicating potential fraud and investor losses.

Negative May 18, 2026 • 22:24 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BW

Rosen Law Firm is soliciting investors who purchased securities of Babcock & Wilcox Enterprises, Aldeyra Therapeutics, and Upstart Holdings during specified periods to join class action lawsuits. The B&W lawsuit alleges the company made false statements regarding a Power Generation contract with Applied Digital, with undisclosed conflicts of interest involving its largest shareholder BRC Group Holdings. The firm emphasizes its track record in securities litigation and encourages investors to act before the June 15, 2026 lead plaintiff deadline.

BW BWNB BWPA ALDX securities class action lead plaintiff deadline false statements investor compensation

Sentiment note

Subject of a securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations or misstatements by the company.

Negative May 18, 2026 • 17:00 UTC GlobeNewswire Inc. • Levi & Korsinsky

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Disregarded FDA Requirements: Levi & Korsinsky

Aldeyra Therapeutics faces a securities class action lawsuit after an FDA Complete Response Letter exposed alleged failures in clinical trial evidence for its lead dry eye disease drug reproxalap. ALDX shares collapsed 70.7% on March 17, 2026, closing at $1.24. Investors who purchased securities between November 3, 2023 and March 16, 2026 can apply to be lead plaintiff by May 29, 2026.

ALDX securities fraud class action lawsuit FDA Complete Response Letter clinical trial failures reproxalap dry eye disease stock collapse

Sentiment note

Company faces securities fraud allegations regarding false and misleading statements about clinical trial efficacy. FDA rejected the drug application citing unreliable study results. Stock experienced a catastrophic 70.7% single-day decline, resulting in significant investor losses.

Negative May 13, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. alleging that the company made false and misleading statements regarding reproxalap clinical trial results. The complaint claims trial results were inconsistent and unreliable, rendering statements about the company's business and prospects materially false. Investors who purchased Aldeyra securities between November 3, 2023 and March 16, 2026 may be eligible to join the lawsuit.

ALDX class action lawsuit securities fraud clinical trial results reproxalap investor harm misleading statements lead plaintiff deadline

Sentiment note

The company is accused of making false and misleading statements about clinical trial results for its drug candidate reproxalap. Allegations of inconsistent trial results and lack of reasonable basis for positive claims indicate serious regulatory and reputational concerns that would negatively impact investor confidence and stock value.

Negative May 12, 2026 • 00:47 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th

A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for allegedly issuing false and misleading statements regarding reproxalap clinical trial results. The lawsuit covers investors who purchased securities between November 3, 2023 and March 16, 2026. Investors have until May 29, 2026 to apply as lead plaintiff.

ALDX class action lawsuit securities fraud clinical trial results misleading statements investor losses reproxalap

Sentiment note

The company is accused of issuing false and misleading statements about clinical trial results and failing to disclose material adverse facts. The lawsuit alleges inconsistent trial results that rendered positive findings unreliable, indicating potential fraud and business integrity concerns.